Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.

British journal of haematology - 1 Oct 2015

Loghavi Sanam, Al-Ibraheemi Alyaa, Zuo Zhuang, Garcia-Manero Guillermo, Yabe Mariko, Wang Sa A, Kantarjian Hagop M, Yin Cameron C, Miranda Roberto N, Luthra Raja, Medeiros L Jeffrey, Bueso-Ramos Carlos E, Khoury Joseph D

Abstract excerpt

Bone marrow (BM) fibrosis is associated with poor prognosis in patients with de novo myelodysplastic syndromes (MDS). TP53 mutations and TP53 (p53) overexpression in MDS are also associated with poor patient outcomes. The prevalence and significance of TP53 mutations and TP53 overexpression in MDS with fibrosis are unknown. We studied 67 patients with de novo MDS demonstrating moderate to severe reticulin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fibrosis

Share to Gene Expression Regulation

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Survival Rate

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 26123119
DOI: 10.1111/bjh.13529
PMCID: PMC5577911

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.PMID 26123119Read ↗

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemiaSemantic proximity Read ↗

Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.Semantic proximity Read ↗

Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53.Semantic proximity Read ↗

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.Semantic proximity Read ↗

TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings.Semantic proximity Read ↗

Clinical outcomes and characteristics of patients with TP53-mutated myelodysplastic syndromes.Semantic proximity Read ↗

TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.Semantic proximity Read ↗

Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes.Semantic proximity Read ↗

High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome.Semantic proximity Read ↗

Exploring p53 protein expression and its link to TP53 mutation in myelodysplasia-related malignancies-Interpretive challenges and potential field of applications.Semantic proximity Read ↗

Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis.Semantic proximity Read ↗

TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.